The impact of media attention, family history, politics and maturation on women’s decisions regarding hormone replacement therapy

Health Care for Women International

Volumn 19, Issue 3, 1998, Pages 243-260

  Andrist, Linda C ^a  

^a MGH INSTITUTE OF HEALTH PROFESSIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; ATTITUDE TO HEALTH; DECISION MAKING; ESTROGEN THERAPY; FAMILY; FEMALE; HUMAN; MASS MEDIUM; MIDDLE AGED; PATIENT ATTITUDE; POLITICS; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE;

ADULT; AGE FACTORS; DECISION MAKING; ESTROGEN REPLACEMENT THERAPY; FAMILY; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MASS MEDIA; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; POLITICS; QUESTIONNAIRES; WOMEN;

EID: 0032067931     PISSN: 07399332     EISSN: 10964665     Source Type: Journal    
DOI: 10.1080/073993398246403     Document Type: Article

References (57)

1. Andrist, L. C. (1993). A model of women-centered practice: Shared decision-making between breast cancer surgeons and patients [CD-ROM]. Abstract from ProQuest File: Dissertation Abstracts Item: 9322337.
2. Avis, N. E., & McKinlay, S. M. (1991). A longitudinal analysis of women’ s attitudes toward the menopause: Results from the Massachusetts Women’ s Health Study. Maturitas, 13, 65-79.
3. Barrett-Connor, E., & Bush, T. L. (1991). Estrogen and coronary heart disease in women. Journal of the American Medical Association, 265, 1861-1867.
4. Baum, M. (1997). Sex steroids and malignancies. Osteoporosis International, 7, (Suppl. 1), S18-S22.
5. Books in Print. (1993-1994, 1995-1996). New Providence, NJ: Reed Reference Publishing.
6. Bush, T. L. (1992). Feminine forever revisited: Menopausal hormone replacement therapy in the 1990’ s. Journal of Women’ s Health, 1(1), 1-4.
7. Bush, T. L., Barrett-Connor, E., Cowan, L. D., Criqui, M. H., Wallace, R. B., Suchindran, C. M., Tyroler, H. A., & Rifkind, B. M. (1987). Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation, 75, 1102-1109.
8. Calle, E. E. (1997). Hormone replacement therapy and colorectal cancer: Interpreting the evidence. Cancer Causes and Control, 8, 127-129.
9. Delmas, P. D. (1997). Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporosis International, 7, (Suppl. 1), S3-S7.
10. Ettinger, B., & Grady, D. (1994). Maximizing the benefit of estrogen therapy for prevention of osteoporosis. Menopause: The Journal of the North American Menopause Society, 1(1), 19-24.
11. Field, P. A., & Morse, J. M. (1985). Nursing research: The application of qualitative measures. Rockville, MD: Aspen.
12. Fillit, H., & Luine, V. (1996). The neurobiology of gonadal hormones and cognitive decline in late life. Maturitas, 26, 159-164.
13. Fruin, M. F., & Lutter, J. M. (1993, Summer). A summary of recent findings on women’ s attitudes toward menopause and midlife changes. Melpomene Journal, 12(2), 21-23.
14. Gallagher, J. C., Hulka, B. S., Ravnikar, V., & Villablanca, A. C. (1996). Why HRT makes sense. Patient Care, 30(13), 166-182.
15. Greendale, G. A., Carlson, K. J., & Schiff, I. (1990). Estrogen and progestin therapy to prevent osteoporosis: Attitudes and practices of general internists and gynecologists. Journal of General Internal Medicine, 5, 464-469.
16. Griffiths, F. (1995). Women’ s health concerns. Is the promotion of hormone replacement therapy for prevention important to women? Family Practice, 12(1), 54-59.
17. Griffiths, F., & Jones, K. (1995). The use of hormone replacement therapy; results of a community survey. Family Practice, 12(2), 163-165.
18. Grodstein, F., Stampfer, M. J., Colditz, G. A., Willet, W. C., Manson, J. E., Joffe, M., Rosner, B., Fuchs, C., Hankinson, S. E., Hunter, D. J., Hennekens, C. H., & Speizer, F. E. (1997). Postmenopausal hormone therapy and mortality. The New England Journal of Medicine, 336, 1769-1775.
19. Haapasaari, K., Raudaskoski, T., Kallioinen, M., Suvanto-Luukkonen, E., Kauppila, A., Läärä, E., Risteli, J., & Oikarinen, A. (1997). Systemic therapy with estrogen or estrogen with progestin has no effect on skin collagen in postmenopausal women. Maturitas, 27, 153-162.
20. Healy, B. (1995). PEPI in perspective: Good answers spawn pressing questions. Journal of the American Medical Association, 273, 240-241.
21. Hemminki, E., Kennedy, D. L., Baum, C., & McKinlay, S. (1988). Prescribing patterns of noncontraceptive estrogens and progestins in the United States, 1974-86. American Journal of Public Health, 78, 1478-1481.
22. Henderson, B. E., Paganini-Hill, A., & Ross, R. K. (1988). Estrogen replacement therapy and protection from acute myocardial infarction. American Journal of Obstetrics and Gynecology, 159, 312-317.
23. Herrington, D. M. (1997). Estrogen and heart disease: Trials to prevent tribulations. Maturitas, 27, 199-202.
24. Hulka, B. A. (1994). Links between hormone replacement therapy and neoplasia. Fertility and Sterility, 62 (Suppl. 2), 168s-175s.
25. Jeffe, D. B., Freiman, M., & Fisher, E. B. (1996). Women’ s reasons for using postmenopausal hormone replacement therapy: Preventive medicine or therapeutic aid? Menopause: The Journal of the North American Menopause Society, 3(2), 106-116.
26. Jolleys, J. V., & Olesen, F. (1996). A comparative study of prescribing of hormone replacement therapy in USA and Europe. Maturitas, 23, 47-53.
27. Levine-Silverman, S. (1989). The menopausal hot flash: A Procrustean bed of research. Journal of Advanced Nursing, 14, 939-949.
28. Lindsay, R. (1996). The menopause and osteoporosis. Obstetrics and Gynecology, 87(2) (Supplement), 16s-19s.
29. MacPherson, K. I. (1991). Hormone replacement therapy for menopause: A contrast between medical and women’ s health movement perspectives. In A. M. Voda & R. Conover (Eds.), Proceedings of the 8th conference Society for Menstrual Cycle Research. Salt Lake City, UT: Society for Menstrual Cycle Research.
30. Mara, J. M. (1994). The reader’ s guide to periodical literature. New York: H. Wilson.
31. Mara, J. M. (1995). The reader’ s guide to periodical literature. New York: H. Wilson.
32. Mort, E. A. (1996). Patient preferences in clinical decision-making. The Journal of Family Practice, 42(2), 147-151.
33. National Women’ s Health Network. (1995). Taking hormones and women’ s health: Choices, risks and benefits (4th ed.) [Brochure]. Washington, DC: Author.
34. Paganini-Hill, A. (1997). Does estrogen replacement therapy protect against Alzheimer’ s Disease? Osteoporosis International, 7, (Suppl. 1), S12-S17.
35. Perry, P. A. (1994). Feminist empiricism as a method for inquiry in nursing. Western Journal of Nursing Research, 16(5), 480-494.
36. Prentice, R. L., Rossouw, J. E., Johnson, S. R., Freedman, L. S., & McTiernan, A. (1996). The role of randomized controlled trials in assessing the benefits and risks of long-term hormone replacement therapy: Example of the Women’s Health Initiative. Menopause: The Journal of the North American Menopause Society, 3(2), 71-76.
37. Ravnikar, V. A. (1987). Compliance with hormone therapy. American Journal of Obstetrics and Gynecology, 156, 1332-1334.
38. Rosenberg, L. (1993). Hormone replacement therapy: The need for reconsideration. American Journal of Public Health, 83, 1670-1673.
39. Rossouw, J. E., Finnegan, L. P., Harlan, W. R., Pinn, V. W., Clifford, C., & McGowan, J. A. (1995). The evolution of the women’s health initiative: Perspectives from the NIH. Journal of the American Medical Women’s Association, 50(2), 50-55.
40. Ryan, P. J., Harrison, R., Blake, G. M., & Fogelman, I. (1992). Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. British Journal of Obstetrics and Gynaecology, 99, 325-328.
41. Schiff, I. (1995, October). Estrogen replacement therapy: Emphasis on breast cancer risk. Primary Care Newsletter, 7(7), 125-132.
42. Schiff, I. (1996). Summing up the risk benefit equation. Menopause: The Journal of the North American Menopause Society, 3(2), 61-64.
43. Shelley, J. M., Smith, M. A., Dudley, E., & Dennerstein, L. (1995). Use of hormone replacement therapy by Melbourne women. Australian Journal of Public Health, 19, 387-392.
44. Smith, D. C., Prentice, R., Thompson, D. J., & Herman, W. L. (1975). Association of exogenous estrogen and endometrial carcinoma among users of conjugated estrogens. New England Journal of Medicine, 293, 1164-1167.
45. Speroff, L. (1996). Postmenopausal hormone replacement therapy and breast cancer. Obstetrics and Gynecology, 87 (Suppl.), 44s-54s.
46. Stampfer, M. J., Colditz, G. A., Willet, W. C., Manson, J. E., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1991). Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses’ Health Study. New England Journal of Medicine, 325(11), 756-762.
47. Stampfer, M. J., Willet, E. C., Colditz, G. A., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1985). A prospective study of postmenopausal estrogen therapy and coronary heart disease. New England Journal of Medicine, 313, 1044-1049.
48. The Writing Group for the PEPI Trial. (1995). Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. Journal of the American Medical Association, 273, 199-208.
49. Tohme, J., Cosmn, F., & Lindsay, R., (1995). Osteoporosis. In K. L. Becker (Ed.), Principles and practices of endocrinology and metabolism (2nd ed., pp. 567-585). Philadelphia: J. B. Lippincott.
50. Utian, W. H. (1996). Determining the role of long-term hormone replacement therapy after menopause in the context of primary preventive health care for women. Menopause: The Journal of the North American Menopause Society, 3(2), 65-70.
51. Utian, W. H., & Schiff, I. (1994). NAMS-Gallup Survey on women’ s knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause: The Journal of the North American Menopause Society, 1(1), 39-48.
52. Voda, A. M. (1994). Risks and benefits associated with hormonal and surgical therapies for healthy midlife women. Western Journal of Nursing Research, 16, 507-523.
53. Weiss, N. S., Ure, C. L., Ballard, J. H., William, A. R., & Daling, J. R. (1980). De- creased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. New England Journal of Medicine, 303, 1195-1198.
54. Wentz, W. B. (1974). Progestin therapy in endometrial hyperplasia. Gynecological Oncology, 2, 362-367.
55. Woods, N. F., & Mitchell, E. S. (1995). Midlife women: Decisions about using hormone replacement therapy for preventing disease in old age. In B. J. McElmurry & R. S. Parker (Eds.), Annual review of women’ s health (Vol. 2). New York: National League for Nursing Press, Publication Number 19-2669.
56. Zhang, Y., Kiel, D. P., Kreger, B. E., Cupples, L. A., Ellison, R. C., Dorgan, J. F., Schatzkin, A., Levy, D., & Felson, D. T. (1997). Bone mass and the risk of breast cancer among postmenopausal women. The New England Journal of Medicine, 336, 611-617.
57. Ziel, H. K., & Finkle, W. D. (1975). Increased risk of endometrial carcinoma among users of conjugated estrogens. New England Journal of Medicine, 293, 1167-1170.